---
figid: PMC11718844__cancers-17-00055-g005
figtitle: Key approved pharmacological agents for the IL-23R pathway
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC11718844
filename: cancers-17-00055-g005.jpg
figlink: /pmc/articles/PMC11718844/figure/F5/
number: F5
caption: Key approved pharmacological agents for the IL-23R pathway. The figure illustrates
  the principal authorized pharmacological agents that interfere with IL-23R or its
  downstream effectors and impede the IL-23R signaling pathway. Created in BioRender.
  www.biorender.com/ (accessed on 20 December 2024)
papertitle: 'The IL-23R and Its Genetic Variants: A Hitherto Unforeseen Bridge Between
  the Immune System and Cancer Development'
reftext: Salvatore Audia, et al. Cancers (Basel). 2025 Jan;17(1).
year: '2025'
doi: 10.3390/cancers17010055
journal_title: Cancers
journal_nlm_ta: Cancers (Basel)
publisher_name: Multidisciplinary Digital Publishing Institute  (MDPI)
keywords: IL-23R | immune cells | genetic variants | Th17 | tumor microenvironment
automl_pathway: 0.9490727
figid_alias: PMC11718844__F5
figtype: Figure
redirect_from: /figures/PMC11718844__F5
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC11718844__cancers-17-00055-g005.html
  '@type': Dataset
  description: Key approved pharmacological agents for the IL-23R pathway. The figure
    illustrates the principal authorized pharmacological agents that interfere with
    IL-23R or its downstream effectors and impede the IL-23R signaling pathway. Created
    in BioRender. www.biorender.com/ (accessed on 20 December 2024)
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IL37
  - IL23A
  - IL12B
  - IL23R
  - TYK2
  - JAK2
  - IL17A
---
